Article Text
Abstract
EU Regulation 536/2014 stipulates that when assessing applications for authorisation to conduct clinical trials, Member States should formulate a ‘single decision’. This raises the problem of identifying: (1) the facility designated to express this ‘single decision’ and (2) the role of ethics committees in the decision-making process. The article addresses the consequences of the requirement that for each Member State the assessment of an application for approval to conduct a trial must take the form of a ‘single decision’ by the Member State concerned. Three possible approaches to the procedures for expressing that ‘single decision’ and to the role of ethics committees in the decision-making process are described, one of which is indicated as the preferred option.
- Clinical trials
- Ethics Committees/Consultation
- Law
- Regulation
Statistics from Altmetric.com
Linked Articles
Read the full text or download the PDF:
Other content recommended for you
- What are local issues? The problem of the local review of research
- Ethics committees for biomedical research in some African emerging countries: which establishment for which independence? A comparison with the USA and Canada
- Implementation of the EU clinical trial regulation transforms the ethics committee systems and endangers ethical standards
- Meeting the challenges facing research ethics committees: some practical suggestions
- Procedures for ethical review for clinical trials within the EU
- Education of ethics committee members: experiences from Croatia
- Multicentre research ethics committees: has the cure been worse than the disease?
- The new system of review by multicentre research ethics committees: prospective study
- A cross-sectional survey to investigate community understanding of medical research ethics committees
- Research ethics committees: the role of ethics in a regulatory authority